OakChart

Evogene Ltd

EVGNHealthcare·Biotechnology·Israel·Nano·NASD·Nov 11 • 4:00 PM ET

0.3954+0.0234 (6.29%)
2026-11-12 04:09 CET
Market cap
7.14 USD m
Revenue, TTM
1.31 USD m
Net income, TTM
-9.07 USD m
Free cash flow, TTM
-11.89 USD m
EPS diluted, TTM
-0.91
P/E
-
Compare

Price

EVGN against its 20, 50 and 200-day averages
2050200earnings
0.400.600.801.0030.2M60.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26EVGNclose 0.4020-day 0.3650-day 0.42200-day 0.640.4052w low

69.1% under the 52-week high of 1.28 on 11 Nov 2025. 52-week low 0.25 on 6 Nov 2026. Last 15 sessions, 72.0% high to low

Volume 0.26× normal · the line is the 50-bar volume average

Profile

EVGN
52-week range, 14% of the way up
0.251.28

Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. It operates through the following segments: Agriculture, Industrial Applications, and Human Health. The Agriculture segment develops seed traits, agrochemical products, and agro biological products to improve plant performance. The Industrial Applications focuses on the development and commercialization of improved castor bean seeds for industrial uses. The Human Health segment involves discovery and development of human microbiome-based therapeutics. The company was founded by Amir Barzilay and Hagai Karchi on October 10, 1999 and is headquartered in Rehovot, Israel.

Employees52
IPOMar 05, 2008
Beta1.42
ATR, 14d0.05
Rel volume0.26
Short float0.62%
Insider own36.98%
Inst own1.98%

Snapshot

6 groups

Valuation

Index-
Market Cap7.14M
Enterprise Value8.95M
Income-9.07M
Sales1.31M
Book/sh-0.24
Cash/sh0.52
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees52
IPOMar 05, 2008

Ratios

P/E-
Forward P/E-
PEG-
P/S5.45
P/B-
P/C0.76
P/FCF-
EV/EBITDA-
EV/Sales6.83
Quick Ratio3.54
Current Ratio3.57
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.91
EPS next Y-0.60
EPS next Q-0.19
EPS this Y-2.08%
EPS next Y45.45%
EPS next 5Y25.25%
EPS past 3/5Y44.96% 33.52%
Sales past 3/5Y32.01% 29.94%
EPS Y/Y TTM59.44%
Sales Y/Y TTM-80.59%
EPS Q/Q76.53%
Sales Q/Q-60.75%
EarningsNov 19 BMO
EPS/Sales Surpr.48.15% 6.77%

Ownership

Insider Own36.98%
Insider Trans23.29%
Inst Own1.98%
Inst Trans4.40%
ROA-71.03%
ROE-
ROIC-
Gross Margin-14.15%
Oper. Margin-1019.82%
Profit Margin-694.19%
SMA209.34%
SMA50-5.03%
SMA200-37.80%
Trades-

Technical

Shs Outstand13.54M
Shs Float11.38M
Short Float0.62%
Short Ratio0.05
Short Interest0.07M
52W High1.28 -69.11%
52W Low0.25 57.97%
Volatility23.52% 10.22%
ATR (14)0.05
RSI (14)53.86
Beta1.42
Rel Volume0.26
Avg Volume1.42M
Volume372,134

Performance

Perf Week10.82%
Perf Month1.33%
Perf Quarter-39.26%
Perf Half Y-47.97%
Perf YTD-64.05%
Perf Year-68.11%
Perf 3Y-93.00%
Perf 5Y-98.45%
Perf 10Y-99.33%
Recom1.00
Target Price2.15
Prev Close0.37
Price0.40
Change %6.29%

Analyst ratings

latest 4 of 4
DateActionAnalystRating changeTargetImplied
Oct 08, 2021InitiatedRROTH CapitalBuy$7+1,670.4%
Jul 29, 2021InitiatedAAegis CapitalBuy$10+2,429.1%
Dec 01, 2020InitiatedCCantor FitzgeraldOverweight$9+2,176.2%
Dec 16, 2013InitiatedOOppenheimerOutperform$26+6,475.6%

Peers

Mkt cap
TickerCompanyMkt cap
CBUSCibus Inc88.66M
MLECMoolec Science SA0.62M
DNAGinkgo Bioworks Holdings Inc679.14M
DYAIDyadic International Inc, DE15.54M
CDXSCodexis Inc106.93M
CLGNCollPlant Biotechnologies Ltd7.48M
RXRXRecursion Pharmaceuticals Inc2.24B
ABSIAbsci Corp1.74B
EXOZeXoZymes Inc37.13M

Insider trading

3 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Tarcic GabiChief Development OfficerJun 04 '26Buy0.601,1296771,129Aug 26 04:00 PM
RECANATI LEONDirectorAug 11 '26Buy0.64460,000292,1001,343,886Aug 13 07:00 AM
RECANATI LEONDirectorAug 04 '26Buy0.50800,000400,000883,886Aug 05 04:07 PM

News

latest 14 of 100

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-19--0.190--0.371
2026Q22026-08-18-0.140-0.270-0.1400.350.331
2026Q12026-05-20-0.600-0.270-0.6030.330.351
2025Q42026-03-05-0.609-0.260-0.6090.310.281
2025Q32025-11-200.444-0.4100.4440.310.651
2025Q22025-08-19-0.500-0.630-0.6180.880.932
2025Q12025-05-21-0.380-0.505-0.3812.444.422
2024Q42025-03-060.060-0.7250.0631.613.632
2024Q32024-11-21-1.310-1.010-1.3141.802.852
2024Q22024-08-22-1.060-1.250-1.0640.910.782
2024Q12024-05-23-0.800-0.950-0.7634.193.382
2023Q42024-03-07-1.300-1.400-1.3050.580.482
2023Q32023-11-15-0.800-1.567-0.8143.771.203
2023Q22023-08-17-1.700-1.750-1.6860.650.892
2023Q12023-05-18-1.500-1.600-1.5120.640.692
2022Q42023-03-09-0.700-2.000-0.7270.660.452

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-8.100--8.0601.75-
2020FY-8.300-8.200-8.3010.500.00
2021FY-6.900-7.167-6.8740.930.62
2022FY-6.500-7.600-6.4641.681.20
2023FY-5.200-5.650-5.2275.645.54
2024FY-2.890-4.115-2.8948.5110.53
2025FY-1.078-0.620-1.0783.853.92
2026FY--1.100--1.44
2027FY--0.600--2.60
2028FY--0.450--4.95
2029FY--0.350--8.30
2030FY--0.250--14.15

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-09-291010.370.370.37
2026Q3S2026-08-181000.400.400.40
2026Q3S2026-05-201000.400.400.40
2026Q3S2026-03-121000.400.400.40
2026Q3S2025-09-221004.004.004.00
2026Q3S2025-09-211004.004.004.00
2026Q3S2025-09-201004.004.004.00
2026Q3S2025-09-191004.004.004.00
2026Q3S2025-09-181004.004.004.00
2026Q3S2025-09-171004.004.004.00
2026Q3S2025-09-161004.004.004.00
2026Q3S2025-09-151004.004.004.00
2026Q3S2025-09-141004.004.004.00
2026Q3S2025-09-131004.004.004.00

Estimate history

EPS, annual-8.117-8.06-7.033-8.301-6.874-6.464-5.227-2.894-1.078-0.9122
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.064-1.3140.063-0.381-0.6180.444-0.609-0.603-0.145
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual3.3811.7470.7531.040.931.6755.645.5773.8531.31
Period201720182019202020212022202320242025TTM
Sales, quarterly0.9141.7961.6112.4440.8840.3120.3140.3340.347
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual2.5752.5752.5753.564.1174.1265.0586.5158.71813.536
Period201720182019202020212022202320242025MRQ
Shares, quarterly5.0976.7936.7966.6728.7148.7168.71810.41313.536
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue1.313.855.585.641.680.931.040.751.75
Cost of Goods Sold Incl. D&A1.492.993.564.243.453.003.303.103.31
Gross Profit-0.180.862.011.40-1.77-2.07-2.26-2.35-1.56
Selling, General and Administrative Excl. Other10.9612.6820.3527.7927.9429.4224.5720.3919.69
Research and Development5.526.9211.3818.1117.5319.4316.6014.6214.09
Other Operating Expense-2.180.000.000.000.000.000.000.00
Operating Income-13.33-14.00-18.34-26.39-29.71-31.49-26.84-22.74-21.25
Interest Expense4.860.190.120.170.240.400.270.350.14
Unusual Expense0.00-0.79-2.860.210.840.432.33-0.401.41
Net Income Before Taxes-15.55-13.46-14.77-25.99-29.75-30.43-26.17-19.09-20.78
Income Taxes0.010.000.01-0.030.090.010.030.020.03
Consolidated Net Income-15.57-13.50-14.82-25.95-29.84-30.45-26.21-19.12-20.81
Net Income From Continuing Operations-16.82-14.16-13.25-23.88-26.64-27.79-23.37-18.11-20.76
Net Income-9.07-8.49-16.49-23.88-26.64-27.79-23.37-18.11-20.76
EPS (Recurring)-0.74-1.15-3.24-5.19-6.32-6.80-7.72-7.14-7.68
EPS (Basic, Before Extraordinaries)-0.91-1.08-2.89-5.23-6.46-6.87-8.30-7.03-8.06
EPS (Diluted)-0.91-1.08-2.89-5.23-6.46-6.87-8.30-7.03-8.06
EBITDA-12.43-12.92-17.15-23.78-27.14-29.26-24.11-19.97-19.23
Non-Operating Income (Expense)2.64-0.060.830.781.041.893.263.612.02
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-0.500.961.450.912.013.151.201.32
Price To Sales Ratio4.102.251.916.8017.2271.30127.2651.9929.19
Gross Margin-14.1522.3236.0924.80-105.91-222.69-217.40-312.08-89.52
Operating Margin-1,019.82-363.28-328.81-467.93-1,774.03-3,386.02-2,580.29-3,019.92-1,216.60
Net Margin-694.19-220.22-295.59-423.39-1,590.33-2,988.49-2,247.50-2,405.31-1,188.21
Shares Outstanding13.548.726.515.064.134.123.562.582.58
Market Capitalization7.147.1410.0334.6628.8567.52167.3239.1550.99

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.350.330.310.310.882.441.611.80
Cost of Goods Sold Incl. D&A0.360.330.370.440.432.191.351.71
Gross Profit-0.010.00-0.05-0.130.460.250.260.09
Selling, General and Administrative Excl. Other2.433.182.762.593.534.574.837.54
Research and Development1.231.641.561.092.032.632.813.80
Other Operating Expense0.00-2.18--0.000.00-
Operating Income-2.44-3.18-4.99-2.71-3.07-4.32-4.57-7.46
Interest Expense0.173.880.350.450.630.460.142.91
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-1.59-5.86-5.38-2.71-3.46-2.990.02-8.21
Income Taxes0.000.000.000.000.000.000.010.00
Consolidated Net Income-1.59-5.91-5.34-2.73-3.53-2.99-0.01-8.22
Net Income From Continuing Operations-1.59-5.88-5.29-4.05-3.31-2.590.43-7.63
Net Income-1.77-5.87-5.313.87-4.46-2.590.43-7.63
EPS (Recurring)-0.14-0.60-0.610.44-0.62-0.380.06-1.31
EPS (Basic, Before Extraordinaries)-0.14-0.60-0.610.44-0.62-0.380.06-1.31
EPS (Diluted)-0.14-0.60-0.610.44-0.62-0.380.06-1.31
EBITDA-2.29-2.98-4.73-2.43-2.78-3.74-3.97-6.83
Non-Operating Income (Expense)1.021.20-0.040.460.241.794.732.15
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Price To Sales Ratio4.104.072.431.901.371.261.492.38
Gross Margin-2.310.60-16.88-40.3851.8110.2716.334.90
Operating Margin-703.46-952.10-1,590.13-870.19-347.40-176.64-283.49-415.09
Net Margin-509.51-1,757.49-1,690.761,241.67-504.75-105.8526.51-424.83
Shares Outstanding13.5410.418.728.728.716.676.806.79
Market Capitalization7.146.719.599.958.546.7110.0315.53

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments12.9915.3131.0635.3953.9448.2846.9254.4771.75
Short Term Receivables0.471.090.670.701.172.171.210.750.81
Inventories0.213.181.690.570.090.000.000.000.00
Other Current Assets1.410.701.041.101.691.380.890.280.22
Total Current Assets15.0820.2934.4737.7556.8951.8249.0355.4972.79
Net Property, Plant & Equipment2.644.253.444.074.183.945.253.194.79
Total Investments and Advances0.040.080.000.000.000.000.000.000.00
Intangible Assets0.0012.2013.1714.1415.2116.1417.070.000.00
Deferred Tax Assets--0.000.09-----
Other Assets2.293.050.030.070.030.010.010.020.02
Total Assets20.0539.8651.1056.1376.3071.9271.3658.6977.60
Short Term Debt Incl. Current Port. of LT Debt0.720.590.850.880.970.780.900.000.00
Accounts Payable0.641.231.781.041.460.861.001.011.11
Other Current Liabilities2.0916.884.313.714.458.043.834.423.55
Total Current Liabilities3.4418.706.945.626.889.685.735.434.66
Long Term Debt1.481.910.280.931.701.662.080.000.00
Provision for Risks Charges0.000.000.000.000.000.000.010.030.03
Other Liabilities0.070.0910.7610.110.000.000.010.030.09
Total Liabilities5.0020.7017.9916.678.5811.347.825.494.79
Non-Equity Reserves3.074.334.434.674.313.693.332.903.44
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-0.08-1.4512.0527.9353.6546.0550.1450.0569.38
Total Shareholders Equity-0.08-1.4512.0527.9353.6546.0550.1450.0569.38
Accumulated Minority Interest12.0616.2916.636.869.7710.8410.070.250.00
Total Equity11.9714.8428.6834.7963.4256.8860.2250.3169.38
Total Liabilities & Stockholders Equity20.0539.8651.1056.1376.3071.9271.3658.6977.60
Book Value Per Share-0.01-0.222.386.7713.0312.9319.4719.4326.94
Tangible Book Value Per Share-0.01-2.09-0.223.349.348.4012.8419.4326.94
Full-Time Employees52117142137141131143150165
Price to Book Ratio-1.63-2.921.870.941.263.630.781.021.05
Return on Assets-47.26-29.13-44.54-40.23-37.50-32.63-27.85-30.46-24.01
Return on Equity--249.92-119.45-65.30-55.75-48.60-36.15-34.76-26.60
Return on Invested Capital-606.07-3,560.48-193.54-92.29-50.22-48.99-34.68-41.47-30.04
Quick Ratio4.320.924.726.618.255.368.5610.2215.61
Current Ratio4.381.094.966.718.275.368.5610.2215.61

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-16.22-13.50-14.82-25.95-29.84-30.45-26.21-19.12-20.81
Depreciation0.951.141.382.612.582.232.732.772.02
Other Funds (Non Cash)3.990.11-3.652.174.361.845.41-0.323.79
Funds from Operations-11.27-12.25-17.09-21.18-22.91-26.37-18.07-16.67-15.00
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.59-1.25-2.61-0.40-0.771.66-1.45-1.00-0.16
Cash from Operating Activities-11.86-13.50-19.70-21.58-23.68-24.72-19.51-17.67-15.16
Capital Expenditures-0.03-0.14-0.63-0.79-1.17-0.85-0.68-0.90-0.37
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.200.080.010.030.000.000.0010.000.00
Purchase or Sale of Investments3.34-0.0010.19-3.7814.45-19.7210.1038.0417.73
Purchase of Investments3.34-0.00-17.15-10.70-0.91-24.110.00-1.64-45.91
Sale Or Maturity of Investments0.000.0027.346.9215.364.4010.1039.6863.64
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources18.8917.800.050.000.000.000.000.000.00
Cash from Investing Activities22.4017.749.62-4.5413.27-20.579.4247.1417.35
Cash Dividends Paid-2.740.000.000.000.000.000.000.000.00
Change in Capital Stock4.364.285.6217.970.0330.0720.720.000.01
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock4.364.285.6217.970.0330.0720.720.000.01
Proceedsfrom Stock Options5.374.280.1217.970.0229.5820.660.000.00
Issuance or Reduction of Debt, Net-0.000.000.000.000.000.000.000.00
Change in Long Term Debt-0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt-0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt-0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-10.94-10.36-0.081.0210.120.790.30-0.100.29
Other Financing Activities Uses-10.94-10.36-0.30-0.07-0.03-0.03-0.02-0.59-0.07
Cash from Financing Activities-9.82-6.604.6618.159.3430.2820.37-0.690.30
Exchange Rate Effect-0.010.02-0.05-0.25-2.281.101.210.16-0.11
Net Change in Cash0.71-2.35-5.47-8.21-3.35-13.9011.4828.942.38
Free Cash Flow-11.89-13.64-20.33-22.36-24.85-25.56-20.20-18.57-15.54
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments9.3513.0912.9915.9611.699.85
Short Term Receivables0.380.290.470.381.112.64
Inventories0.090.170.212.111.962.15
Other Current Assets1.031.421.411.6112.900.65
Total Current Assets10.8514.9615.0820.0627.6515.29
Net Property, Plant & Equipment2.062.412.643.363.714.10
Total Investments and Advances0.000.000.040.000.010.08
Intangible Assets--0.000.000.0011.96
Other Assets0.530.582.292.212.552.88
Total Assets13.4417.9520.0526.0933.9334.30
Short Term Debt Incl. Current Port. of LT Debt0.670.650.720.680.680.67
Accounts Payable0.390.460.640.460.560.59
Other Current Liabilities1.984.252.092.9413.9614.34
Total Current Liabilities3.045.363.444.0815.1915.60
Long Term Debt1.431.381.481.841.981.92
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.070.070.070.080.100.09
Total Liabilities4.546.815.006.0017.2717.61
Non-Equity Reserves3.133.153.072.844.284.30
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-3.29-2.54-0.081.14-3.55-3.65
Total Shareholders Equity-3.29-2.54-0.081.14-3.55-3.65
Accumulated Minority Interest9.0610.5412.0616.1115.9316.04
Total Equity5.777.9911.9717.2512.3812.39
Total Liabilities & Stockholders Equity13.4417.9520.0526.0933.9334.30
Book Value Per Share-0.24-0.24-0.010.13-0.41-0.55
Tangible Book Value Per Share-0.24-0.24-0.010.13-0.41-2.34
Full-Time Employees--52---
Price to Book Ratio-1.63-81.838.40-2.80-2.34-1.96
Return on Assets-71.03-70.96-50.88-28.77-34.98-37.51
Return on Equity------655.00
Return on Invested Capital---379.21129.70--
Quick Ratio3.542.764.324.411.690.84
Current Ratio3.572.794.384.921.820.98

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-1.45-5.91-5.78-3.08-2.47-2.99
Depreciation0.140.200.290.320.020.58
Other Funds (Non Cash)-0.872.692.74-0.57--
Funds from Operations-2.18-3.02-2.75-3.33--
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.080.07-0.26-0.471.20-1.80
Cash from Operating Activities-2.10-2.95-3.01-3.80-7.510.00
Capital Expenditures-0.01-0.00-0.01-0.01-0.00-0.12
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.090.020.050.030.000.00
Purchase or Sale of Investments4.53-4.537.74-4.40-1.02-2.33
Purchase of Investments4.53-4.537.74-4.40-1.02-2.33
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.010.023.2215.640.020.00
Cash from Investing Activities4.62-4.4911.0011.26-1.00-2.45
Cash Dividends Paid-2.55-0.190.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.913.210.060.184.300.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.913.210.060.184.300.00
Proceedsfrom Stock Options0.830.000.064.480.000.00
Issuance or Reduction of Debt, Net-0.000.00--0.00
Change in Long Term Debt-0.000.00--0.00
Issuance of Long Term Debt-0.000.00--0.00
Reduction of Long Term Debt-0.00---0.00
Net Financing Active Other Cash Flow-0.070.10-0.28-10.690.01-0.02
Other Financing Activities Uses-0.070.00-0.28-10.58-0.00-0.12
Cash from Financing Activities-1.812.99-0.37-10.644.17-0.16
Exchange Rate Effect-0.010.000.01-0.010.04-0.02
Net Change in Cash0.71-4.457.63-3.190.88-7.81
Free Cash Flow-2.11-2.96-3.02-3.81-7.52-0.12

Revenue breakdown

Israel2024: 5.58M 2025: 3.85M
Agriculture2024: 2.96M 2025: 1.37M
Human2024: 80.00K
Industry2024: 2.22M 2025: 2.17M
Unallocated2024: 323.00K 2025: 311.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.62%0.1M11.4M1.40M
2026-10-150.56%0.1M11.4M1.43M
2026-09-309.36%0.9M10.0M1.99M
2026-09-150.57%0.1M10.0M1.48M
2026-08-310.53%0.1M10.0M1.86M
2026-08-142.13%0.2M10.9M1.86M
2026-07-310.41%0.0M11.0M1.69M
2026-07-152.68%0.2M9.3M1.69M
2026-06-301.73%0.2M12.0M1.08M
2026-06-152.61%0.3M12.0M511.51K
2026-05-291.03%0.1M12.0M100.25K
2026-05-151.29%0.2M12.0M100.31K
2026-04-301.65%0.2M9.8M481.72K
2026-04-151.73%0.2M9.8M484.25K
2026-03-312.77%0.2M8.6M480.85K
2026-03-132.81%0.2M8.6M462.57K
2026-02-272.18%0.2M8.6M431.66K
2026-02-133.16%0.3M8.6M429.22K
2026-01-300.87%0.1M8.6M46.11K
2026-01-150.87%0.1M8.6M54.93K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-10SEC
2026-10-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-28SEC
2026-10-223Initial statement of beneficial ownership of securities2026-10-06SEC
2026-10-223Initial statement of beneficial ownership of securities2026-10-06SEC
2026-10-06SCHEDULE 13D/ASEC
2026-10-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-06SEC
2026-09-304Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-09-304Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-09-304Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-09-304Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-09-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-30SEC
2026-09-29EFFECTEffectiveness filing by commission orderSEC
2026-09-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-09-28POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-09-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-15SEC
2026-09-11SCHEDULE 13D/ASEC
2026-09-11SCHEDULE 13D/ASEC
2026-09-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-04SEC
2026-08-28SCHEDULE 13D/ASEC
2026-08-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-27SEC
2026-08-264Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-08-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-18SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13SCHEDULE 13D/ASEC
2026-08-13SCHEDULE 13D/ASEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-08-11SCHEDULE 13DSEC
2026-08-07SCHEDULE 13D/ASEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-07-316-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-08692.10K200
2026-070000
2026-06677100
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
HRT FINANCIAL LP0.89%
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.66%
CITADEL ADVISORS LLC0.42%
XTX Topco Ltd0.16%
BNP PARIBAS FINANCIAL MARKETS0.02%
MORGAN STANLEY0.01%
Federation des caisses Desjardins du Quebec0.00%
Daytona Street Capital LLC0.00%
OSAIC HOLDINGS, INC.0.00%
UBS Group AG0.00%

Funds

Fund% owned
Goldman Sachs Income Builder Fund1.67%
THE CONTINENTAL SMALL COMPANY SERIES0.30%
INTERNATIONAL CORE EQUITY 2 PORTFOLIO0.26%
Dimensional International Small Cap ETF0.17%
Dimensional International Core Equity 2 ETF0.10%
Dimensional International Core Equity Market ETF0.09%
Fidelity Total International Index Fund0.07%
Dimensional World ex. U.S. Core Equity 2 ETF0.06%
Dimensional International Small Cap Value ETF0.05%
Fidelity Nasdaq Composite Index Fund0.03%

OakChart. EVGN. Cached 15 minutes.